Tempus AI RWD Deals: Merck & Gilead 2026 Pricing Analysis
Analyze Tempus AI's Q1 2026 nine-figure real-world data (RWD) and AI modeling agreements with Merck and Gilead to understand the evolution of RWD pricing.
Back to Articles
Articles tagged with “oncology-research”
AI Foundation Models in Pharma: GSK-Noetik Oncology Deal
Examine the $50M GSK-Noetik agreement licensing AI foundation models for oncology. Learn how spatial biology and virtual cells advance R&D and drug discovery.